Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
August 11, 2022
Earnings Call Speaker Segments
Jennifer Good
executiveThanks for joining us this afternoon, everyone, for our discussion of second quarter results and the latest on the business. With me today are Trevi's Chief Financial Officer, Lisa Delfini, and our Chief Development Officer, Dr. Bill Forbes. Lisa and I have some prepared remarks to share, and once that's done, the three of us will be happy to answer your questions. This has been an exciting year at Trevi, and the second quarter continued that pattern. After the encouraging interim cost data we shared in the first quarter, we reported results during the second quarter from our prurigo nodularis trial, or PN, and those were statistically significant as well. From where we stand, this gave us meaningful confirmation that Haduvio's distinctive mechanism — working through both central and peripheral pathways — is relevant to the conditions we've chosen to pursue. Among the most serious elements of these diseases are cough and idiopathic pulmonary fibrosis, or IPF, as well as pruritus and PN. Our belief is that in each of these two conditions, there may be a chance to influence the disease at its root; as an example, in the PN trial we showed that excoriations could heal, since 55% of subjects on Haduvio had an improvement of at least one category on the five-point Prurigo Activity Scale, compared with 38% for placebo, yielding a p-value of 0.006 at week 14. I'll now bring you up to date on both development programs. Turning to chronic cough and IPF — we're really enthusiastic about where this indication is heading. For patients with cough and IPF, Haduvio is the top candidate in development and the sole one that has produced favorable data in a blinded trial. Cough is a major unmet need among the IPF population, since most of these individuals say coughing is among the most troubling features of their condition. In our upcoming study, we also intend to look at additional aspects of the disease itself to determine whether lowering cough affects health outcomes. As I noted earlier, during the first quarter we shared results from this trial's interim analysis that were highly statistically significant. After we proved the concept worked, we collaborated with our locations to stop enrolling sooner and complete the trial. During the interim review, we shared findings for the 26 participants who had gotten through at minimum treatment period 1, which was the full analysis set, plus 18 participants who had finished the entire crossover involving both treatment periods in the study. Ultimately, 38 participants were enrolled for the whole trial. We're awaiting the complete data collection covering every participant in the study, along with the unblinded safety findings, and we anticipate reporting results for the entire group of participants during this quarter. Additionally, this autumn we'll share findings from our cough program — covering both the interim and complete datasets — at scientific congresses. The first of these is the European Respiratory Society gathering in Barcelona during September, where the interim results earned us a slot for oral delivery. Beyond that, we've been busy laying groundwork for the subsequent cough trial. Our contract research organization partner is now on board, we're identifying which countries and sites to use, and a draft protocol is in progress that we intend to take up with the FDA during a meeting scheduled for this quarter. After the design is finalized, we'll come back to you with an update and guidance on the anticipated timing for the study and its readout. Prurigo nodularis, or PN, is our additional target indication—a severe, debilitating condition marked by skin papules and nodules plus relentless, intense itching. Given how refractory this disease is, we think PN is neurologically driven and could match up nicely with Haduvio's neuronal mechanism. The majority of these individuals have already gone through and not succeeded with topical options; we expect that future patients will qualify for an oral treatment such as Haduvio prior to moving on to biologics. As noted earlier, we announced positive results at the close of Q2 from the Phase 2b/3 PRISM study in PN. Statistical significance was reached on the primary endpoint and every key secondary endpoint. When the top line data was released, the final key secondary endpoint—the PROMIS sleep scale—was still pending. We're happy to share that the PROMIS sleep scale likewise backed the overall favorable findings, with subjects on Haduvio seeing considerably larger gains on the PROMIS measure compared with placebo, yielding a p-value of 0.0002 at week 14. During week six of the trial, the first PROMIS assessment took place, and it showed a statistically significant benefit as well. So we're very pleased that both the primary endpoint and every key secondary endpoint produced positive results, and that Haduvio demonstrated an early response. This information has been accepted for an oral presentation at the European Academy of Dermatology and Venereology in September, and I plan to attend if any of you will be there. For the PN program, the next steps are to complete the one-year open-label extension study. The last patient is scheduled to complete one year in January 2023. In the meantime, we will continue reviewing the blinded data and preparing a request for an end of Phase 2 meeting with the FDA. This past year has been extremely busy for everyone at Trevi. The results from our trials have given us a solid foundation to pursue possible expansion in both of those primary indications, along with additional opportunities that may arise through life cycle management. Just to recap, during the current quarter we expect to receive the full CANAL dataset covering cough and IPF, hold a meeting with the FDA regarding cough and IPF, and host an R&D Day later in the quarter where we will present our forward-looking strategy and development plans. At this point I'll hand things over to Lisa, who will walk us through the financial results, and afterward we'll open the floor for questions.
Lisa Delfini
executiveThanks, Jennifer. Good afternoon, everybody. Just a quick note that you can find the complete financial results for the three and six months that ended June 30, 2022 in the press release we put out before this call, as well as in our 10-Q, which we filed with the SEC today once the market closed. During the second quarter of 2022, our net loss came in at $8.1 million, versus a net loss of $9.8 million in the same quarter of 2021. R&D expenses totaled $5.1 million in the second quarter of 2022, down from $6.5 million in the comparable period of 2021. That decline mostly reflected fewer purchases of clinical trial supplies and clinical trials subject to recruitment costs, less spending on consulting services, and the fact that professional recruiting fees tied to hiring in the prior year period did not repeat. G&A expenses came to $2.7 million in the second quarter of 2022, unchanged from the same period of 2021. As I mentioned on last quarter's call, we raised roughly $55 million in early April by selling common stock and prefunded warrants. That offering was priced at the market with no warrant coverage. Now that we have more cash on hand and interest rates are climbing, we're putting our cash into a portfolio of high credit quality marketable securities to generate interest income. We also brought in proceeds of $5.9 million during the second quarter from the exercise of warrants originally issued in our October 2021 private placement. Our cash, cash equivalents and marketable securities balance stood at $78.9 million at the end of June; in July we received an additional $4.1 million in proceeds, again from the exercise of warrants issued in our October 2021 private placement. That leaves us ending July with a cash, cash equivalents and marketable securities balance of about $79.8 million. This provides us with cash runway into Q4 of 2023 to fund our ongoing operations, including finishing the open-label extension of the PRISM trial, as Jennifer mentioned, and getting ready for the end of Phase 2 meeting with the FDA, plus planning for and running our next trial for chronic cough in IPF; on top of that, we currently have roughly 11 million warrants still outstanding, which could bring in up to $15 million in proceeds if they get exercised. Because of the $55 million raise in April, our cap table has become a bit more complicated, so I wanted to walk you through it. As of today, we have 42.8 million shares outstanding. In the April private placement, we also issued 24.4 million prefunded warrants; they're called prefunded warrants since substantially all of the strike prices are paid when they're issued. So even though they aren't legally outstanding, they have to be included in how we calculate weighted average shares outstanding and basic and diluted loss per share; also, as I noted earlier, we have approximately 11 million warrants outstanding from our October 2021 private placement and 4.1 million stock options outstanding. Alright, our fully diluted share count stands at just above 82 million. We keep reducing the term loan, and its principal amount has fallen below $11 million at this point. To wrap up, we're enthusiastic about the data recently announced in PN, along with how solid our balance sheet is, which lets us keep carrying out our plan; that brings our prepared remarks to an end. At this time I'll hand the call back to the operator so we can move into Q&A.
Annabel Samimy
analystThank you for taking my questions. I'm just wondering — and I know it's probably a bit early, since the final chronic cough data still need to be reported out — do you have any sense of what a Phase 3 could look like, drawing on what other companies have run in, say, idiopathic or refractory chronic cough, and how big it would need to be? Then, on the PROMIS scale, could you remind us what that scale includes, so we can gauge how meaningful that endpoint is? And last, on PN: I believe there are now a few more targeted antibodies that have read out. Clearly, Dupixent has filed and is waiting on a PDUFA for PN. And Galderma has — sorry, the name just slipped my mind — their program is in its second Phase 3 trial. I know you're oral and might get there sooner. But what's your hunch about how that development or competitive landscape could play out? Might it boost awareness of PN? Or might it hurt your opportunity in PN? I'd just like a sense of how you're viewing it, as things start heating up in this space. Thanks.
Jennifer Good
executiveThanks, Annabel. Bill, would you like to handle the first two — trial design and the PROMIS scale — and then I can cover the competitive landscape?
Bill Forbes
executiveYes, absolutely. Hello, Annabel, and thank you for asking. I'll begin with <<inaudible>>, even though your first question was about <<inaudible>>, which is the upcoming trial we're conducting in IPF. Let me provide some context regarding the PROMIS scale. To step back for a moment, as you're aware, PRISM included three key secondary endpoints. The ItchyQoL and the Prurigo Activity Scale, as Jennifer mentioned, have already been reported. Now we have the PROMIS sleep disturbance measure, which is the short form we employed. It contains eight items. This instrument was originally created as a broad tool for evaluating sleep within controlled clinical trials, and that's how we applied it here. Basically, as I mentioned, there are eight open-ended statements, each with five response choices. Those choices span from very poor to very good, or from not at all to very much. The items focus on sleep and its quality. So I hope that gives you some clarity regarding the PROMIS portion. Naturally, it reached statistical significance at six — pardon me, at months one, two, and three of fixed dose. We were quite pleased to report those results. With CANAL, you're correct that additional data is still forthcoming. However, because the data we already have is so strong, we don't anticipate much of a difference. That said, we will be able to share some new findings; we'll examine the 24-hour data alongside what we previously reported. You should expect roughly a 50% increase in the volume of data available in that upcoming readout. Looking ahead to <<inaudible>>, what we've told the FDA in preparation for an upcoming meeting is that we'd like to conduct a six-month trial with three treatment arms; so we'll take — currently, we're considering a primary endpoint based on the digital cost monitor at weeks two and four, then monthly thereafter across the six months. We'll likely set the primary endpoint early, at one month. But naturally, since we'll collect additional data in the months that follow, we'll have that information regarding durability as well. I think the question we frequently hear is why run a six-month trial, since the onset clearly doesn't take long. Well, the onset of effect with nalbuphine is extremely rapid. Therefore, the purpose for that half-year period is to gather key safety data that we think will improve our grasp of the way nalbuphine might impact such individuals. You can picture measures along the lines of FVC, and additionally hospitalizations due to respiratory reasons are among the things that interest us. It permitted us to extend out to six months with two active doses. That provides us with roughly 100 patient exposure years. Consequently, we will manage to build up sufficient safety information within this population to genuinely achieve a solid comprehension of the safety and, naturally, the efficacy as well. So with any luck, Annabel, that is useful to you.
Annabel Samimy
analystAll right, that's been quite useful. Appreciate it.
Bill Forbes
executiveWould you like to take the…
Jennifer Good
executiveYes. No, I'm glad to address that — the competitive landscape. So Annabel, you've tracked us for a long enough time to understand that around UP or PN, we reached a fork in the road. And really, we made our choice mostly due to the biologics in that area and, in a way, what we believed they could do to help develop the market. Plus, pricing would be placed at a favorable level, in my view, to mirror the disease state. And so we've always understood they would be present. I think whenever you speak with dermatologists, there's also, in a way, a treatment paradigm that they adhere to, which goes topical to oral to biologics. So not everyone will always stick to that, but I think there is a substantial unmet need in that oral systemic portion of this entire equation. So on the whole, I think it's positive. We clearly knew they were present — both dupi and nemolizumab, which is the one you couldn't recall. So no, it's not — I believe it actually benefits the market overall. No, I realize it's a tough one to remember. And we believe we can compete. If you examine the dupi data, in a way, the weak three months, which is roughly where we read out, we're in a way in the same swim lane on delta. They subsequently reported a six-month trial, which becomes much bigger. And I think that's in a way the hallmark of this disease. You're attempting to break that itch scratch cycle. And overall nodules heal, which you're already seeing at three months; and as time passes, it's really — there's really an exponential effect. So as Bill is able to open up the open-label extension data, hopefully, we'll be able to share more of, in a way, the impact of that longer term.
Annabel Samimy
analystPerfect, thank you.
Lisa Delfini
executiveYes, thank you.
Serge Belanger
analystHello there, good afternoon. We've got a few questions for you. First, regarding the cough indication, I'm wondering what your thoughts are right now on looking at indications outside of IPF cost, and whether that's something you intend to bring up with the agency during the meeting that's coming up; then about PN, I believe you have yet another FDA meeting for that indication. I'm just wondering what the objective is going to be for that particular agency meeting. Thank you.
Jennifer Good
executiveSure. Let's take those one at a time. When it comes to cough, we are exploring other indications outside of IPF. That isn't a topic we'll raise with the agency at our meeting; our focus is really going to remain on that program, to lock it down and secure agreement there; we're holding some internal discussions over the summer. That's the reason we are — as I said in my comments, we'll hold an R&D Day probably in the back half of September, where we can clearly present the development strategy regarding indications, along with time lines and some trial guidance, et cetera. So Serge, watch for that, where we'll be clear about what lies beyond IPF if we decide to pursue any additional life cycle management opportunities. Regarding PN, you're correct, we actually still have our end of Phase 2 meeting in front of us. So we'll make the most of it; that's a significant meeting. We'll bring in the data, review it with them, and discuss what we hope will be our final pivotal trial in order to secure approval. So it's been some time since we last checked in with the agency on that program. But I do believe much of that has come together with the other competitors in the space.
Serge Belanger
analystSo as things stand right now with the PN program, is it still your expectation that just a single extra Phase 3 trial would be required? That's right, isn't it?
Jennifer Good
executiveCorrect. Bill, would you like to take that one?
Bill Forbes
executiveRight. That is what we're anticipating — though we're always open to seizing a good opening. Still, pointing everyone toward a single additional study strikes me as the best course of action in this situation. Everyone, I believe, has now had the opportunity to review the results. They are clearly robust. A great deal of solid data is contained within them. That said, when it comes to this — for that particular indication — running one more trial is the sensible move.
Serge Belanger
analystOkay, thank you.
Jennifer Good
executiveThank you, Serge.
Leland Gershell
analystHello, and good afternoon. I appreciate you answering my questions. I just wanted to inquire about expectations for timing. I realize it's somewhat early, and we'll do our best to remain patient regarding the R&D Day in late September. Still, do you have any indication of when the next trials might begin across both indications as we move into 2023? Thank you.
Jennifer Good
executiveSure. So Leland, regarding IPF-cough, where we've been pushing harder and completing tasks, our aim is to get that underway during the first half of next year. As for PN, we're still gathering all the data and need to ask for our FDA meeting, and we're handling those efforts simultaneously. Consequently, we lack sufficient clarity on that program at this point to likely provide solid guidance. However, with IPF-cough, we're working toward launching it in the first half of next year or sooner.
Leland Gershell
analystAll right. Excellent; now I have one additional item. When you consider strategically the nice dilemma presented by having two possible uses for Haduvio, is there anything you can tell us about how your thinking has changed regarding which one to put first? Or is it truly the case that both will proceed side by side as you move toward the approval process? Thanks.
Jennifer Good
executiveYeah, that's a fair question, and it's something that requires constant attention. Somewhat of a rhythm is going to be necessary. Still, let me give an example: with PN, we are quite familiar with this area; we've run studies there, and the protocols are more or less laid out. Our CRO collaborators are already secured. So that one ought to progress. Our Clin Ops group is fully engaged with it. IPF-cough gained some early advantage thanks to the interim data. So we will simply arrange the timeline in a sensible way and figure it out; however, my sense is mostly—and Bill, I'd like you to weigh in as well—my sense is mostly that both ought to be capable of advancing at approximately the same pace.
Bill Forbes
executiveYeah, I figure that's where the challenge lies — making sure everything keeps moving at the same time.
Leland Gershell
analystThanks a lot, and I appreciate you taking the time to answer.
Lisa Delfini
executiveOf course, Leland — thanks to you.
Nathan Weinstein
analystHello Jennifer, Lisa, and Bill — thanks for taking my questions. There were two things I wanted to ask. The first follows up on PROMIS as it relates to sleep. Could you help us understand this from the angle of patients, along with what you've been hearing back from physicians? In what way do patients handle sleep? Within the PN indication, are they struggling with sleep? That's my first question.
Jennifer Good
executiveHi Bill — would you like to handle that one, or should I?
Bill Forbes
executiveRight. No, I've spoken with a few of the investigators involved in this one. And as you'd expect with a condition that comes with intense itching, being able to sleep well ranks very high among what they're hoping to address. You can picture how much anxiety these unfortunate patients endure, itching throughout the entire day and then, naturally, being unable to get any rest; so the sleep element is something we feel great about. Being capable of shifting the scales the way we've managed to, we believe that demonstrates a clinically meaningful type of improvement at this stage with the PROMIS; we're still presenting it to some investigators and thought leaders, but we're pleased with it.
Nathan Weinstein
analystThanks, that's helpful. I've got one more question, about the CRO partner you've brought on for the upcoming cough study. If you don't mind, could you remind me — is this the same CRO that you've been using? And regarding the trial locations, is there going to be a lot of overlap with the places where you've previously enrolled patients?
Jennifer Good
executiveYes; regarding the CRO partnership, since we're bound by a CDA, I'm not able to name them, but this is a partner we've worked with during the prior trial; they've been excellent. So that's good, a fairly smooth launch. As for the PN sites, there will definitely be overlap with the sites we used previously. For cough, we will — the UK will be one of the countries we return to. But remember, we conducted that only in the UK. So now we'll need to expand into the U.S., and we're also exploring opportunities in other countries.
Nathan Weinstein
analystUnderstood. Appreciate it, and congratulations on a really impressive opening six months of the year. We're eager to see what the second half brings.
Jennifer Good
executiveThanks, Nathan.
Jennifer Good
executiveEveryone, thanks for joining us on this call today. I hope the remainder of your summer is enjoyable for all of you. Thanks.
Operator
operatorThat brings today's call to a close. We appreciate your joining this presentation. You're welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.